Keyphrases
Anti-infliximab Antibodies
33%
Coefficient of Variation
16%
Crohn's Disease
100%
Enzyme-linked Immunosorbent Assay (ELISA)
75%
Fluid Phase
8%
IgG4-related Disease (IgG4-RD)
8%
Infliximab
100%
Linear Correlation
16%
Low Limit of Detection
8%
Pooled Serum
8%
Radioimmunoassay
41%
Reporter Gene Assay
66%
Result Reproducibility
8%
Same Patient
8%
Solid Phase
8%
Systematic Difference
8%
Titer
16%
Immunology and Microbiology
Crohn's Disease
100%
Enzyme Immunoassay
18%
Enzyme-Linked Immunosorbent Assay
37%
Immunoglobulin G4
6%
Infliximab
100%
Liquid
6%
Radioimmunoassay
31%
Reporter Gene
50%
Solid
6%
Titer
12%
Pharmacology, Toxicology and Pharmaceutical Science
Crohn's Disease
100%
Enzyme Immunoassay
18%
Enzyme-Linked Immunosorbent Assay
37%
Immunoglobulin G4
6%
Infliximab
100%
Radioimmunoassay
31%
Biochemistry, Genetics and Molecular Biology
Enzyme
56%
Immunoassay
18%
Infliximab
100%
Liquid
6%
Reporter Gene
50%
Solid
6%
Titer
12%
Food Science
Enzyme-Linked Immunosorbent Assay
100%